コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ve disease (PD) of irradiated HCC by RECIST (Response Evaluation Criteria in Solid Tumors).
2 esponses were evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors).
3 end point was objective response status (per Response Evaluation Criteria in Solid Tumors).
4 se was assessed every 2 months using RECIST (Response Evaluation Criteria in Solid Tumors).
5 tive response rate (ORR), defined by RECIST (Response Evaluation Criteria in Solid Tumors).
6 esponse was classified according to modified Response Evaluation Criteria in Solid Tumors.
7 rast-enhanced MRI and CT on the basis of the Response Evaluation Criteria in Solid Tumors.
8 riteria, and tumour response was measured by Response Evaluation Criteria In Solid Tumors.
9 nical response was determined at 3 months by Response Evaluation Criteria In Solid Tumors.
10 ed threshold of >or= 20% activity defined by Response Evaluation Criteria in Solid Tumors.
11 e patients had partial response according to Response Evaluation Criteria in Solid Tumors.
12 essing progression and response according to Response Evaluation Criteria in Solid Tumors.
13 l is more relevant than clinical response by Response Evaluation Criteria in Solid Tumors.
14 int was overall response rate as assessed by Response Evaluation Criteria in Solid Tumors.
15 evaluated for objective clinical response by Response Evaluation Criteria in Solid Tumors.
16 on-free survival (PFS), and best response by Response Evaluation Criteria in Solid Tumors.
17 ry 8 weeks by computed tomography scan using Response Evaluation Criteria in Solid Tumors.
18 ges in the size of the tumor on CT using the response evaluation criteria in solid tumors.
19 Tumor response was evaluated by CT using Response Evaluation Criteria In Solid Tumors.
20 lus stable disease) was 94% according to the response evaluation criteria in solid tumors.
21 DEB-TACE response was based on modified Response Evaluation Criteria in Solid Tumors.
22 of efficacy was tumor response according to Response Evaluation Criteria in Solid Tumors.
23 ent was objective tumor response (by RECIST [Response Evaluation Criteria in Solid Tumors]).
26 a masked independent review committee using Response Evaluation Criteria in Solid Tumors 1.1 in the
27 esion diameters were determined according to Response Evaluation Criteria in Solid Tumors 1.1 on CT (
30 evaluated for tumor response by using RECIST Response Evaluation Criteria in Solid Tumors 1.1, origin
34 n responders and nonresponders were based on Response Evaluation Criteria in Solid Tumors and CA-125
35 The authors then summarize the conventional Response Evaluation Criteria in Solid Tumors and World H
37 med partial response (ie, 32.5% reduction by Response Evaluation Criteria in Solid Tumors) and withdr
39 Clinical response was evaluated according to Response Evaluation Criteria in Solid Tumors, and FDG-PE
40 8 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an
41 Radiologic (response evaluation criteria in solid tumors), biochemic
43 with a partial or complete response based on Response Evaluation Criteria in Solid Tumors categories
44 e new international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee.
47 nse by modified World Health Organization or Response Evaluation Criteria In Solid Tumors criteria an
48 tmenopausal women with measurable disease by Response Evaluation Criteria in Solid Tumors criteria wh
49 hin the Milan criteria, tumor response using Response Evaluation Criteria in Solid Tumors criteria, f
51 sessments of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria.
54 ntermittent sunitinib dosing continued until Response Evaluation Criteria in Solid Tumors-defined dis
58 sponse was evaluated every 2 cycles by using Response Evaluation Criteria in Solid Tumors Group crite
59 FU and irinotecan had a partial response by Response Evaluation Criteria in Solid Tumors Group crite
60 complete or partial response (as defined by Response Evaluation Criteria in Solid Tumors Group or 50
61 sociated with a disease control rate of 95% (Response Evaluation Criteria in Solid Tumors Group)/100%
62 e patients were evaluated for response using Response Evaluation Criteria in Solid Tumors Group, and
63 disease progression at 6 months, defined by Response Evaluation Criteria in Solid Tumors Group, Pros
65 s progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines.
67 toward complete/partial response; by RECIST (Response Evaluation Criteria in Solid Tumors), median su
68 to evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) i
69 response was assessed according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
70 response rate, time-to-progression (modified Response Evaluation Criteria in Solid Tumors [mRECIST]),
73 comes compared with that according to RECIST Response Evaluation Criteria in Solid Tumors or original
74 ve was to determine response rate defined by Response Evaluation Criteria in Solid Tumors; other end
76 e, response was evaluated in accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1
77 e Criteria in Solid Tumors (PERCIST 1.0) and Response Evaluation Criteria in Solid Tumors (RECIST 1.1
78 S recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST ver
79 ion-free survival (PFS) assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST) (t
85 both an individual and a patient basis using Response Evaluation Criteria in Solid Tumors (RECIST) 1.
87 onstrate > 80% local control (LC) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.
88 at 12 wk revealed 1 partial response by the response evaluation criteria in solid tumors (RECIST) an
89 sing tumor response at 6 months according to Response Evaluation Criteria in Solid Tumors (RECIST) an
90 tic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) an
91 nse and time to progression according to the Response Evaluation Criteria in Solid Tumors (RECIST) an
95 val (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) as
98 Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) co
99 point was response at 12 weeks determined by Response Evaluation Criteria in Solid Tumors (RECIST) cr
100 en (PSA) decline, with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) cr
101 r radiotherapy and had measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) cr
102 mong the 29 evaluable patients, only 31% met Response Evaluation Criteria in Solid Tumors (RECIST) fo
104 ponse to erlotinib was assessed by using the Response Evaluation Criteria in Solid Tumors (RECIST) on
105 stage I) and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or
106 randomisation, had measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) or
107 f treatment better than standard dimensional Response Evaluation Criteria In Solid Tumors (RECIST) re
108 mary tumors in three dimensions, whereas the Response Evaluation Criteria in Solid Tumors (RECIST) re
109 e) in 16 patients (27%); CT evaluation using Response Evaluation Criteria in Solid Tumors (RECIST) sh
110 endpoints that are based on the categorical Response Evaluation Criteria In Solid Tumors (RECIST) sy
111 ed cell death receptor 1) monotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST) v1
112 mor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1
113 easurable disease as defined in the modified Response Evaluation Criteria In Solid Tumors (RECIST) ve
115 r 1, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) ve
116 ance status of 0 or 1, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) ve
117 by local investigator assessment as per the Response Evaluation Criteria In Solid Tumors (RECIST) ve
118 Antitumor response was assessed according Response Evaluation Criteria in Solid Tumors (RECIST) ve
119 The data warehouse assembled to guide the Response Evaluation Criteria in Solid Tumors (RECIST) ve
122 sponse assessment was also obtained by using response evaluation criteria in solid tumors (RECIST), a
123 orld Health Organization (WHO) criteria, the Response Evaluation Criteria in Solid Tumors (RECIST), a
124 sus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), a
125 y Group (COG) criteria, one-dimensional (1D) Response Evaluation Criteria in Solid Tumors (RECIST), a
126 ld Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), b
127 better than World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), m
129 archival tumor molecular status, response by Response Evaluation Criteria in Solid Tumors (RECIST), p
130 We assessed tumor responses with the use of Response Evaluation Criteria in Solid Tumors (RECIST), p
131 d Health Organization (WHO) criteria and the Response Evaluation Criteria in Solid Tumors (RECIST), r
132 assessed by local radiologists according to Response Evaluation Criteria in Solid Tumors (RECIST), v
133 y central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), v
134 riteria used to evaluate tumor response, the Response Evaluation Criteria in Solid Tumors (RECIST), w
135 benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-de
136 until progression was identified by CT with Response Evaluation Criteria in Solid Tumors (RECIST).
137 ty criteria and tumour responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST).
138 e response was defined by version 1.0 of the Response Evaluation Criteria in Solid Tumors (RECIST).
139 y that led to our current assessment method, Response Evaluation Criteria in Solid Tumors (RECIST).
140 tive clinical responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).
141 s study was to evaluate the response rate by Response Evaluation Criteria in Solid Tumors (RECIST).
142 ervals, and clinical outcome was assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
143 of antitumor activity were redefined by the Response Evaluation Criteria in Solid Tumors (RECIST).
144 nd point of the study was tumor response per Response Evaluation Criteria in Solid Tumors (RECIST).
145 R] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST).
146 ted tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST).
147 measurable lesion by CT or MRI according to Response Evaluation Criteria In Solid Tumors (RECIST); E
148 with centrally reviewed overall response per Response Evaluation Criteria In Solid Tumors (RECIST, ve
149 verall response rate (ORR) assessed with the Response Evaluation Criteria In Solid Tumors (RECIST, ve
150 3% met criteria for progression according to Response Evaluation Criteria in Solid Tumors (RECIST; >/
151 essed based on investigator review using the Response Evaluation Criteria in Solid Tumors (RECIST; ve
152 n EGFR TKI; systemic progression of disease (Response Evaluation Criteria in Solid Tumors [RECIST] or
155 were safety and overall response (defined by Response Evaluation Criteria In Solid Tumors [RECIST] ve
156 included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] ve
157 apy with unselected young TILs (according to Response Evaluation Criteria in Solid Tumors [RECIST]),
158 progressive measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST], v
164 f > or = 30% and > or = 90%; rate of RECIST (Response Evaluation Criteria in Solid Tumors) responses
165 Clinical activity (by RECIST [Response Evaluation Criteria in Solid Tumors]), survival
166 osttherapy CT images were evaluated by using Response Evaluation Criteria in Solid Tumors, the Choi c
167 UVmax and best response according to RECIST (Response Evaluation Criteria in Solid Tumors), there was
168 point was response according to RECIST 1.0 (Response Evaluation Criteria in Solid Tumors) using mult
169 imary end points were CR rate (as defined by Response Evaluation Criteria in Solid Tumors v1.0) and o
170 carcinoma, measurable disease (according to Response Evaluation Criteria In Solid Tumors v1.1), East
171 Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, centr
172 objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.0
173 nce status of 0-1, and measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1
174 dently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1
175 least one measurable lesion according to the Response Evaluation Criteria In Solid Tumors version 1.1
176 ponse was assessed every 12 weeks by central Response Evaluation Criteria in Solid Tumors version 1.1
177 n randomisation and progression according to Response Evaluation Criteria In Solid Tumors version 1.1
178 ed complete response or partial response per Response Evaluation Criteria In Solid Tumors version 1.1
179 on-squamous histology, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1
180 f 0 or 1, at least one measurable lesion per Response Evaluation Criteria In Solid Tumors version 1.1
181 scalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1
182 was progression-free survival, determined by Response Evaluation Criteria in Solid Tumors version 1.1
183 ry end points assessed clinical activity per Response Evaluation Criteria in Solid Tumors version 1.1
184 1 or less, measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1
185 tus of 0 or 1, measurable disease defined by Response Evaluation Criteria In Solid Tumors version 1.1
186 as assessed every 8 weeks in accordance with Response Evaluation Criteria in Solid Tumors version 1.1
187 24-week progression-free survival rate (per Response Evaluation Criteria in Solid Tumors version 1.1
188 ormance status 0 or 1, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1
189 ed complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1
190 t was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1
191 f 1 or less, measurable disease according to Response Evaluation Criteria In Solid Tumors version 1.1
192 ents with an objective response, assessed by Response Evaluation Criteria In Solid Tumors version 1.1
193 ne gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1
194 estigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.
195 urvival by local investigator assessment per Response Evaluation Criteria In Solid Tumors (version 1.
196 urvival by local investigator assessment per Response Evaluation Criteria In Solid Tumors (version 1.
197 ry six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.
198 mary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.
199 e primary endpoint was response according to Response Evaluation Criteria in Solid Tumors, version 1.
200 by PD-L1 expression status according to the Response Evaluation Criteria in Solid Tumors, version 1.
201 sponse, or stable disease according to local Response Evaluation Criteria in Solid Tumors, version 1.
202 immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.
203 nse by an independent review committee using Response Evaluation Criteria in Solid Tumors, version 1.
204 was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.
205 rimary end point was clinical benefit (using Response Evaluation Criteria in Solid Tumors, version 1.
206 by blinded independent central review using Response Evaluation Criteria in Solid Tumors, version 1.
207 either as an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.
209 ime to disease progression (according to the Response Evaluation Criteria in Solid Tumors, version 1.
211 , and anatomic tumor response as measured by Response Evaluation Criteria in Solid Tumors was investi
214 fore and 1 month after PVE were measured and Response Evaluation Criteria in Solid Tumors were applie
215 survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%,
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。